Takeda's brigatinib (Alunbrig) received its latest U.S. Food and Drug Administration (FDA) approval for the treatment of anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) in patients who have had at least one other tyrosine kinase inhibitor (TKI) therapy [1][2]. This expanded the drug's indication beyond its initial approval for ALK+ metastatic NSCLC in patients who have progressed on or are intolerant to crizotinib [2].
How does Alunbrig work for ALK-positive NSCLC?
Brigatinib is an ALK inhibitor that targets the ALK gene rearrangement, which drives the growth of certain NSCLC tumors [2]. It works by blocking the signaling pathways that promote cancer cell proliferation and survival [2].
When did Alunbrig first get FDA approval?
Alunbrig first received FDA approval on April 29, 2017, for patients with ALK-positive metastatic NSCLC who progressed on or were intolerant to crizotinib [1][2].
What are the key differences in the latest FDA approval for Alunbrig?
The latest U.S. regulatory outcome, an expansion of its indication, allows brigatinib to be used in a broader patient population. Previously approved for patients who had already received at least one TKI, the new approval permits its use in ALK+ metastatic NSCLC patients who have had at least one other TKI therapy [1][2].
What clinical data supported the expanded approval of Alunbrig?
The expanded approval was based on data from the ALTA-1L trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients treated with brigatinib compared to crizotinib as a first-line treatment for ALK-positive advanced NSCLC [1][2].
What are the main side effects associated with Alunbrig?
Common side effects of brigatinib include diarrhea, fatigue, nausea, rash, cough, hypertension, and dyspnea [2]. More serious side effects can include interstitial lung disease, hepatotoxicity, and bradycardia [2].
How does brigatinib compare to other ALK inhibitors?
Brigatinib is one of several ALK inhibitors available for treating ALK-positive NSCLC. Other notable drugs in this class include crizotinib, alectinib, ceritinib, and lorlatinib [3]. Each drug has demonstrated varying efficacy and safety profiles in clinical trials, and treatment decisions often depend on the patient's prior treatment history, specific genetic mutations, and overall health [3][4].
When does the patent for Alunbrig expire?
Information regarding the specific patent expiration dates for brigatinib is available through specialized databases. For detailed patent timelines and exclusivity periods, resources like DrugPatentWatch.com can provide comprehensive data [5].
Who manufactures Alunbrig in the United States?
Alunbrig is manufactured by Takeda Pharmaceuticals U.S.A., Inc. [2].
Where can I find more detailed information on brigatinib's regulatory status and clinical trials?
Detailed information on brigatinib's regulatory history, clinical trial data, and approved indications can be found on the U.S. Food and Drug Administration's website, as well as through pharmaceutical industry databases and scientific literature [1][2][3][4].
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/fda-drug-safety-communication-information-regarding-takedas-alunbrig-brigatinib
[2] https://www.alunbrig.com/
[3] https://www.cancer.gov/about-cancer/treatment/drugs/brigatinib
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1910471
[5] https://drugpatentwatch.com/